January 2018 Vol. 6 No.1

Search Pubmed for articles by:
 

Original Research Article

Will intervertebral disc diseases be prevented by siRNA or miRNA-based genomic treatment modalities?

Yener AKYUVA¹, Numan KARAARSLAN^2*, Ibrahim YILMAZ³, Tezcan CALISKAN² and Duygu Yasar SIRIN⁴

¹M.D., Gaziosmanpasa Taksim Training and Research Hospital, Department of Neurosurgery, 34433, Istanbul, Turkey
²Assist. Prof. M.D., Namik Kemal University School of Medicine, Department of Neurosurgery, 59100, Tekirdag, Turkey
³Medical Pharmacologist, pharmacist, Istanbul Medipol University School of Medicine, Department of Medical Pharmacology, 34810, Istanbul, Turkey
⁴Assist. Prof. Ph.D., Namik Kemal University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, 59030, Tekirdag, Turkey

*Corresponding Author’s É-mail: numikara@yahoo.com
Phone: +9028 2250 5500

Accepted January 05, 2018

Abstract

In the present study, a systematic review of experimental research carried out by drug delivery systems that allow for drug release in which oligonucleotides are imbrued, such as small interfering-/micro ribonucleic acids, was conducted. The data obtained after an electronic database query with no language limitation were evaluated using statistical methods. Results were shown as frequency. There was no research found that described successfully imbrued oligonucleotides into drug delivery systems that could be used to prevent intervertebral disc degeneration. There is a high possibility that trial target therapies might have a positive effect on nucleus pulposus cell regeneration, which is damaged most in the disc during intervertebral disc degeneration; however, these designs, whose invitro release kinetics have been reported, need to be tested invivo in living subjects after they have been tested for surgical techniques to fill this gap in the literature.

Key Words: Antisense oligonucleotide therapy, Drug delivery systems, Intervertebral disc degeneration, miRNA; nucleus pulposus cell, Post transcriptional gene silencing, siRNA